Sign In
Last checked at 
31 Jan 2023 17:00
31 January 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Total Voting Rights
Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's ("FCA") Disclosure Guidance and Transparency Rules.
As of 31 January 2023, the Company's issued ordinary share capital consists of 347,175,106 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 347,175,106 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
Allenby Capital Limited | +44(0) 20 33285656 |
John Depasquale | |
George Payne |
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | cizzle@investor-focus.co.uk |
Florence Chandler |
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is a spin- out from the University of York that is developing a blood test for the early detection of lung cancer. Its proof-of-concept prototype test is based on the work of Professor Coverley and colleagues to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Follow the stocks
